Fastrack · FDA Orders Eye Risk Warnings for Ozempic, Zepbound

The FDA on Monday ordered makers of GLP-1 drugs to warn of a potential increased risk of NAION. The condition is a rare optic nerve disorder that can cause sudden blindness.

The rule covers Ozempic, Wegovy, Mounjaro, Zepbound and older GLP-1 diabetes drugs.
NAION cases have been reported for every GLP-1 drug now on the market.
FDA scientists could not identify how the drugs might raise the risk.
1 in 10,000 semaglutide users may develop NAION, the EMA estimated.

Why it matters: About 15% of U.S. adults, roughly 40 million people, have used a weight loss drug. The FDA now says patients and caregivers should know about the vision risk.

NAION damage is often permanent, and no known treatment exists.
Diabetes, sleep apnea and hypertension raise NAION risk and are common among GLP-1 users.

How 19 sources split on this story

Source landscape

Factuality

High

Mixed

Low

Strong LeftLeftLean LeftCenterLean RightRightStrong Right

Political Bias

Coverage by lean% of 19 sources

19 sources · 23 articles · 47% Center coverage

Where they split: Coverage differs on whether to stress how rare the condition is or how severe the risk increase and personal harm are.

Center9 sources

USA Today2hDo Ozempic, Zepbound cause vision loss? New FDA warning explained Associated Press4hFDA adds rare vision-loss warning to popular GLP-1 drugs KSAT 12 San Antonio4hFDA adds rare vision-loss warning to popular GLP-1 drugs MarketWatch6hOzempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss PennLive2hFDA says use of popular GLP-1 drugs may lead to a rare but very serious, side effect The Hill3hFDA warns of rare ‘eye stroke’ risk from GLP-1 drugs WFLA News Channel 83hFDA adds rare vision-loss warning to popular GLP-1 drugs WGAL 83hFDA adds warning about rare vision loss to popular GLP-1s WKBN Youngstown4hFDA adds rare vision-loss warning to popular GLP-1 drugs

Left coverage, 7 sources: The left frames it as a regulatory step, noting the condition is rare and the evidence base behind the decision.

NBC News6hFDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness CNN7hUS FDA orders new eye risk warnings for Ozempic, Zepbound The Independent4hFDA adds rare vision-loss warning to popular GLP-1 drugs CBS News11mGLP-1 drugs, popular for weight loss, get FDA warning of rare vision-loss side effect Gizmodo2hFDA Orders New Vision Loss Warning for Ozempic and Other GLP-1s The Boston Globe3hFDA adds rare vision-loss warning to popular GLP-1 drugs The Washington Post3hFDA tells GLP-1 makers to warn of potential vision loss side effect

Right coverage, 3 sources: The right frames it around the blindness risk to users and the patients now suing the drugmakers.

Daily Mail7hFDA issues new warning for Ozempic saying it can cause blindness with 'eye stroke' side effect New York Post3hGLP-1 drugs must have new warning label over incurable blindness condition, says FDA The Epoch Times1dFDA Mandates New Eye Risk Warning on GLP-1 Drugs

What’s next: Drugmakers must add NAION to the warnings and precautions sections of their labels.

Nearly 100 lawsuits have been filed against Novo Nordisk since 2025, with fewer against Eli Lilly.
How common is NAION among people taking GLP-1 drugs?
Is the risk caused by the drugs or by the conditions their users already have?